Pacer Advisors Inc. Buys 922,650 Shares of DexCom, Inc. $DXCM

Pacer Advisors Inc. increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 1,534.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 982,779 shares of the medical device company’s stock after purchasing an additional 922,650 shares during the quarter. Pacer Advisors Inc.’s holdings in DexCom were worth $65,227,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Trust Co. of Vermont grew its holdings in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the last quarter. CVA Family Office LLC lifted its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after buying an additional 178 shares during the period. Personal CFO Solutions LLC boosted its holdings in DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after acquiring an additional 185 shares during the period. Finally, Keel Point LLC boosted its stake in DexCom by 3.1% during the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 193 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ:DXCM opened at $72.47 on Friday. The company has a 50-day moving average of $66.93 and a 200-day moving average of $67.88. The company has a market capitalization of $27.96 billion, a price-to-earnings ratio of 30.97, a PEG ratio of 1.11 and a beta of 1.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 46,694 shares of company stock valued at $3,343,977. 0.28% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DXCM shares. UBS Group set a $95.00 price target on shares of DexCom in a research report on Wednesday, June 10th. William Blair raised shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Bank of America reduced their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. BTIG Research restated a “buy” rating and set a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a report on Monday, June 1st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $84.83.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.